Clinical Trial Update: Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, tolerability, and pharmacokinetics of GSK3923868 in people with chronic obstructive pulmonary disease has completed and resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK3923868 (GSK3923868)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED | Results posted: 2024-10-15